Korea Comirnaty Post-marketing Surveillance

Key facts

Sponsor

Pfizer

Principal Investigator

Pfizer CT.gov Call Center

Pfizer

Intervention

Tozinameran 12 Years of age and older(biological)

Enrollment

12000 target

Eligibility

All sexes

Timeline

2022 – 2026

Study locations (1)

• Pfizer, Seoul, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06099795
  Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2
  Centre Hospitalier Universitaire de Nīmes
• RECRUITINGPHASE4NCT06585241
  A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
  ModernaTX, Inc.
• RECRUITINGNCT06168019
  Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India
  Boston University
• RECRUITINGEARLY PHASE1NCT05656105
  Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection
  University of Alabama at Birmingham
• RECRUITINGNCT05892549
  COVID-19: Early Detection of Worsening by Voice and Respiratory Pattern Characteristics
  Direction Centrale du Service de Santé des Armées
• RECRUITINGNANCT05566483
  Physiology of Long COVID-19 and the Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional Capacity
  University of Colorado, Denver
• ACTIVE NOT RECRUITINGNCT05787964
  Immunity to Infection in Healthy Participants and Participants With Cancer
  University Hospital Tuebingen
• RECRUITINGPHASE2, PHASE3NCT05543616
  A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
  BioNTech SE

See all trials for Severe acute respiratory syndrome →